
STUDY SCHEMA

Advanced Solid Tumor Cancers

- HER2 amplification on MSK-IMPACT (fold change ≥ 2) or another NGS platform at CLIA laboratory, or ISH (HER2/CEP17 ratio \geq 2.0), or
- Lung cancer with HER2 mutation (Cohort 1 only)



Supplementary Figure 2. Consort diagram. The diagram shows TDM-1 clinical trial study scheme